Daflon
DrugAll consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
NCT Number: NCT04512443
The article presents the results of a randomized, placebo-controlled study of the conservative treatment with Daflon (Detralex) in female patients with Pelvic congestion syndrome .
Looking for future studies?
Notify Me18 year–60 year
Female
Observational
Akhmetzianov Rustem, Kazan', Russia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
•The presence of pelvic varicose veins verified by transvaginal and transabdominal duplex ultrasound scanning
Exclusion criteria
All consecutive patients were randomly allocated into 2 groups to receive Daflon (Detralex) at a dose of 1000 mg once daily (study group) or placebo (control group).
Time frame: 2 months
Assessment of quality of life according to the questionnaire before and after treatment
Interregional Clinical Diagnostic Center, Russia
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03921788
Neurologic Manifestations, Pain
Moscow, Russia
View Trial DetailsNCT05889000
Pelvic Congestion Syndrome
Kazan', Tatarstan Republic, Russia
View Trial DetailsNCT02796092
Pelvic Congestion Syndrome
Zaragoza, Spain
View Trial DetailsNCT07472504
Pelvic Congestion Syndrome
View Trial Details